ArticleCancer immunology, immunotherapy : CII2024

First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial.

Qi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.